Short Interest in Senti Biosciences, Inc. (NASDAQ:SNTI) Decreases By 22.7%

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 165,200 shares, a decrease of 22.7% from the March 31st total of 213,800 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average daily volume of 81,400 shares, the short-interest ratio is currently 2.0 days.

Hedge Funds Weigh In On Senti Biosciences

A number of institutional investors have recently added to or reduced their stakes in SNTI. 8VC GP I LLC bought a new stake in shares of Senti Biosciences during the 4th quarter valued at $1,675,000. ARK Investment Management LLC boosted its stake in Senti Biosciences by 7.9% during the fourth quarter. ARK Investment Management LLC now owns 1,969,860 shares of the company’s stock worth $1,300,000 after acquiring an additional 143,785 shares in the last quarter. Finally, TD Asset Management Inc boosted its stake in Senti Biosciences by 88.4% during the third quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock worth $102,000 after acquiring an additional 113,172 shares in the last quarter. Institutional investors own 25.73% of the company’s stock.

Senti Biosciences Stock Performance

Shares of NASDAQ SNTI traded up $0.01 during midday trading on Friday, hitting $0.29. 44,490 shares of the company traded hands, compared to its average volume of 64,939. Senti Biosciences has a 12-month low of $0.27 and a 12-month high of $1.10. The firm has a market cap of $13.27 million, a P/E ratio of -0.18 and a beta of 2.96. The stock has a 50-day moving average price of $0.38 and a 200 day moving average price of $0.41.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative return on equity of 74.59% and a negative net margin of 2,692.82%. As a group, equities analysts expect that Senti Biosciences will post -1 earnings per share for the current year.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.